Editas Medicine Inc. (EDIT)

22.99
0.67 3.00
NASDAQ : Health Technology
Prev Close 22.32
Open 22.32
Day Low/High 21.92 / 23.52
52 Wk Low/High 17.80 / 32.46
Volume 921.47K
Avg Volume 570.60K
Exchange NASDAQ
Shares Outstanding 49.52M
Market Cap 1.01B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of November 22nd Options Trading For Editas Medicine (EDIT)

First Week Of November 22nd Options Trading For Editas Medicine (EDIT)

Investors in Editas Medicine Inc saw new options begin trading this week, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new November 22nd contracts and identified one put and one call contract of particular interest.

Editas Medicine Is Now Oversold (EDIT)

Editas Medicine Is Now Oversold (EDIT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Editas Medicine To Participate In Upcoming Investor Conferences

Editas Medicine To Participate In Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct.

Editas Medicine To Participate In Upcoming Investor Conferences

Editas Medicine To Participate In Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug.

Editas Medicine Announces Second Quarter 2019 Results And Update

Editas Medicine Announces Second Quarter 2019 Results And Update

Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in Brilliance trial on track for 2H19 EDIT-301 for hemoglobinopathies pre-clinical in vivo...

Editas Medicine To Host Conference Call Discussing Second Quarter 2019 Results And Corporate Update

Editas Medicine To Host Conference Call Discussing Second Quarter 2019 Results And Corporate Update

CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.

Allergan And Editas Medicine Initiate The Brilliance Phase 1/2 Clinical Trial Of AGN-151587 (EDIT-101) For The Treatment Of LCA10

Allergan And Editas Medicine Initiate The Brilliance Phase 1/2 Clinical Trial Of AGN-151587 (EDIT-101) For The Treatment Of LCA10

Expect first patient dosing in second half of 2019 DUBLIN, Ireland and CAMBRIDGE, Mass.

Interesting EDIT Put And Call Options For August 9th

Interesting EDIT Put And Call Options For August 9th

Investors in Editas Medicine Inc saw new options begin trading today, for the August 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new August 9th contracts and identified one put and one call contract of particular interest.

EDIT July 12th Options Begin Trading

EDIT July 12th Options Begin Trading

Investors in Editas Medicine Inc saw new options become available today, for the July 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new July 12th contracts and identified one put and one call contract of particular interest.

Interesting EDIT Put And Call Options For June 28th

Interesting EDIT Put And Call Options For June 28th

Investors in Editas Medicine Inc saw new options begin trading today, for the June 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new June 28th contracts and identified one put and one call contract of particular interest.

Interesting EDIT Put And Call Options For April 12th

Interesting EDIT Put And Call Options For April 12th

Investors in Editas Medicine Inc saw new options begin trading today, for the April 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new April 12th contracts and identified one put and one call contract of particular interest.

Interesting EDIT Put And Call Options For March 29th

Interesting EDIT Put And Call Options For March 29th

Investors in Editas Medicine Inc saw new options become available today, for the March 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new March 29th contracts and identified one put and one call contract of particular interest.

March 22nd Options Now Available For Editas Medicine (EDIT)

March 22nd Options Now Available For Editas Medicine (EDIT)

Investors in Editas Medicine Inc saw new options become available today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

Interesting EDIT Put And Call Options For February 22nd

Interesting EDIT Put And Call Options For February 22nd

Investors in Editas Medicine Inc saw new options become available today, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new February 22nd contracts and identified one put and one call contract of particular interest.

Editas Medicine Becomes Oversold (EDIT)

Editas Medicine Becomes Oversold (EDIT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of December 7th Options Trading For Editas Medicine (EDIT)

First Week Of December 7th Options Trading For Editas Medicine (EDIT)

Investors in Editas Medicine Inc saw new options begin trading this week, for the December 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new December 7th contracts and identified one put and one call contract of particular interest.

First Week Of December 21st Options Trading For Editas Medicine (EDIT)

First Week Of December 21st Options Trading For Editas Medicine (EDIT)

Investors in Editas Medicine Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

First Week Of EDIT November 30th Options Trading

First Week Of EDIT November 30th Options Trading

Investors in Editas Medicine Inc saw new options become available this week, for the November 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new November 30th contracts and identified one put and one call contract of particular interest.

Interesting EDIT Put And Call Options For May 2019

Interesting EDIT Put And Call Options For May 2019

Investors in Editas Medicine Inc saw new options become available this week, for the May 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 226 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EDIT October 26th Options Begin Trading

EDIT October 26th Options Begin Trading

Investors in Editas Medicine Inc saw new options become available today, for the October 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new October 26th contracts and identified one put and one call contract of particular interest.

EDIT: Insiders Vs. Shorts

EDIT: Insiders Vs. Shorts

The most recent short interest data was recently released for the 08/15/2018 settlement date, and Editas Medicine Inc is one of the most shorted stocks of the Russell 3000, based on 6.56 "days to cover" versus the median component at 5.05. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

These Stocks Are Still Bargains: Cramer's 'Mad Money' Recap (Monday 7/9/18)

These Stocks Are Still Bargains: Cramer's 'Mad Money' Recap (Monday 7/9/18)

Even after Monday's rally, these stocks are terrific, says Jim Cramer. Here's how to play the great employment numbers.

TheStreet Quant Rating: D (Sell)